Join Factor Bioscience and become part of a team working to invent new technologies to treat disease and improve health.


Our research lab and ISO Class 7 cleanroom facility are both located at our headquarters in Cambridge, Massachusetts.
Associate Scientist, Molecular Biology and Gene-Editing
Factor Bioscience is seeking an exceptional candidate to join our team as Associate Scientist, Molecular Biology and Gene-Editing. This role is a part of the Molecular Biology team and supports development of Factor Bio’s novel UltraSlice gene-editing platform, as well as assisting optimization of nucleic acid delivery for pre-clinical programs. This is a lab-based position that works with state-of-the-art cell, molecular, and synthetic molecular biology techniques.
Associate Scientist
Factor Bioscience is seeking an exceptional candidate to join our team as Associate Scientist. In this position, you will create advanced mRNA and cell-engineering technologies for the development of new medicines for patients with devastating diseases including Parkinson's disease, Crohn's disease, dystrophic epidermolysis bullosa, and cancer.
Associate Scientist (Chemistry)
Factor Bioscience is seeking an exceptional candidate to join our team as Associate Scientist. In this position, you will create advanced mRNA and cell-engineering technologies for the development of new medicines for patients with devastating diseases including Parkinson's disease, Crohn's disease, dystrophic epidermolysis bullosa, and cancer.
February 28, 2023
Factor Bioscience Announces Publication of Preclinical Results of Aerosolized mRNA For the Treatment of Pneumonia
-mRNA encoding immunomodulatory proteins IκBα-SR and SOD3 ameliorated symptoms in bacterial pneumonia model -Factor is investigating nebulized mRNA formulations for other therapeutic indications and next-generation vaccine applications CAMBRIDGE, Mass., February 28, 2023 /PRNewswire/ — Factor Bioscience Inc. (“Factor”), a Cambridge-based biotechnology company focused on developing mRNA and cell-engineering technologies, announced the results of preclinical testing of […]
February 22, 2023
Eterna Therapeutics Enters Into Option and License Agreement With Lineage Cell Therapeutics to Develop Hypoimmune Pluripotent Cell Lines for Multiple Neurology Indications
CAMBRIDGE, MASS. – February 22, 2023 – Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna”), a preclinical-stage biotechnology company committed to realizing the potential of mRNA cell engineering to provide patients with transformational new medicines, today announced that it has entered into an exclusive option and license agreement (the “Agreement”) with Lineage Cell Therapeutics, Inc. (“Lineage”) for the development of novel induced hypoimmune […]
January 4, 2023
Eterna Therapeutics Appoints Matt Angel, Ph.D. as Chief Executive Officer and President
CAMBRIDGE, Mass., Jan. 04, 2023 (GLOBE NEWSWIRE) — Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”), a biopharmaceutical company using advanced cell engineering technology to develop transformational new medicines, today announced the appointment of Matt Angel, Ph.D. as Chief Executive Officer (“CEO”) and President. Dr. Angel has served as Interim CEO and President of Eterna since […]